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Synergy1, a prebiotic composed of Inulin and Oligofructose (1:1). Soybean meal is a natural source of isoﬂavones. The objective
was to investigate the eﬀects of feeding Synergy1 and SM on the incidence of azoxymethane- (AOM-) induced aberrant crypt foci
(ACF) in Fisher 344 male rats. Rats (54) were randomly assigned to 9 groups (n = 6). Control group (C) was fed AIN-93G and
treatment groups Syn1 and SM at 5% and 10% singly and in combinations. Rats were injected with two s/c injections of AOM at
7 and 8 weeks of age at 16mg/kg body weight and killed at 17 weeks by CO2 asphyxiation. Colonic ACF enumeration and hepatic
enzyme activities were measured. Reductions (%) in total ACF among treatment groups fed combinations were higher (67–77)
compared to groups fed singly (52–64). Synergistic mechanisms among phytochemicals may be responsible suggesting protective
role in colon carcinogenesis with implications in food product development.
1.Introduction
Cancer is a major public health problem and statistics
show that colon cancer is the third leading cause of cancer
deaths among men and women in the USA [1]. Primary
prevention is a promising and cost-eﬀective approach in
reducing morbidity and mortality related to cancer. Geo-
graphical variations in colon cancer prevalence are higher
in industrialized nations compared to developing countries
which may be explained by the inﬂuence of environmental
f a c t o r ss u c ha sd i e t[ 2]. Diet is one of the modiﬁable risk
factors which has been found to inﬂuence colonic microﬂora
and their enzymes in colon carcinogenesis [3–5]. Dietary
chemoprevention emerged as one of the strategies targeting
multistage pathogenesis [6]. Chemoprevention is deﬁned
as “use of natural, synthetic, biological or chemical agents
to reverse, suppress, or prevent carcinogenic progression
[7–9].
Epidemiological and experimental studies show a corre-
lation with the consumption of dietary ﬁber and a reduction
in colon cancer [10–12]. Synergy1 is a prebiotic composed of
Inulin and Oligofructose in equal proportion that has shown
inhibitory eﬀects on AOM-induced ACF in F344 rats [13]
explained by stimulation of probiotics, production of short
chain fatty acids, and activation of detoxifying enzymes [14].
Soybean contains a variety of phytochemicals such as
isoﬂavones, phytates, phytosterols, protease inhibitors, acid
phenolics, saponins, and omega-3 fatty acids with numerous
health beneﬁts such as lowering plasma cholesterol, osteo-
porosis, prostate, and breast cancer [15, 16]. Isoﬂavones
are phytoestrogens available as glycosides in plants and are
transformed to aglycones in the human intestine. Action
of intestinal β-glucosidases results in increased absorption
and bioavailability of these bioactive compounds and for-
mationofmetabolitessuchasequol,O-desmethylangolensin
(ODMA) from daidzein, and P-ethylphenol from genistein
[17–21]. The human population consists of equol producers
andnonequolproducersbasedoninterindividualdiﬀerences
in establishment of intestinal microﬂora [22]. Due to its
potential antioxidative properties [23, 24] equol has been2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Composition of dietsa (AIN-93G).
Ingredients Control
(AIN-93G)
Syn1
(5%)
Syn1
(10%)
SM
(5%)
SM
(10%)
Syn1 + SM
(5% + 5%)
Syn1 + SM
(10% + 10%)
Syn1 + SM
(5% + 10%)
Syn1 + SM
(10% + 5%)
Syn1 0 50 100 0 0 50 100 50 100
SM 0 0 0 50 100 50 100 100 50
Corn starch 397.5 347.5 297.5 371.5 345.5 321.5 245.5 295.5 271.5
Casein 200 200 200 180 160 180 160 160 180
F i b e r 5 0 5 0 5 04 64 2 4 6 4 2 4 2 4 6
Common
Ingredientsb 352.5 352.5 352.5 352.5 352.5 352.5 352.5 352.5 352.5
aFormulations of diets based on AIN-93G (Reeves et al., 1993a,b).
bCommonC ingredients (g): soybean oil: 70g; mineral mix (AIN-93G): 35; vitamin mix: 10; L-cysteine: 3; choline bitartrate: 2.5.
Abbreviation used: Syn1: Synergy1, SM: Soybean meal, and AIN-93G: American Institute of Nutrition 93 Growth.
reported to reduce the development of chronic diseases such
as prostate cancer [25] and cardiovascular diseases [26].
Biomarkers aid in the screening and diagnosis of early
stages of pathogenesis [27]. One such early biomarker in
colon carcinogenesis is Aberrant Crypt Foci (ACF)—used in
prescreening the eﬀects of potential chemopreventive agents
and chemical risk assessment in the environment. ACF are
microscopic precancerous lesions in the colon capable of
progressing to tumors [28]. Azoxymethane (AOM) is a
potent carcinogen used to induce colon tumors in rodent
models to determine the chemopreventive eﬃcacy of foods
[29].
Quantitative assays of speciﬁc enzymes activated in
responsetoxenobioticsareusefulbiomarkersindetermining
the chemopreventive potential of speciﬁc diets [30, 31].
Glutathione-S-transferases(GSTs)arecrucialphaseIIdetox-
iﬁcationenzymesthatoﬀerprotectionbycatalyzingconjuga-
tion resulting in excretion of xenobiotics [32, 33]. Catalase
is an antioxidative enzyme involved in the detoxiﬁcation
of hydrogen peroxide. Superoxide-dismutase is an essential
enzyme involved in the conversion of free radical superox-
ides to peroxides [34]. Prebiotics may inﬂuence isoﬂavone
metabolism that can constitute a novel approach in inducing
beneﬁcialmicroﬂora suchasequol-producing and lactic acid
bacteria responsible for healthy bowel function. Previous
research on health beneﬁts of Synergy1 and Soybean has
provided a platform to investigate the eﬀects of Synergy1 and
Soybean meal (SM) singly and in combinations at 5% and
10% on the incidence of aberrant crypt foci (ACF) in Fisher
344 male rats and explore the selected mechanisms of action.
2.Methods and Materials
2.1. Animal Housing and Diets. Fifty-four Fisher 344 male
weanling rats (3 weeks old) were obtained from Harlan, IN
and housed in stainless steel wire cages at 2 rats per cage.
After one week of acclimatization all rats were randomly
assigned to nine groups (n = 6) and fed the following diets:
AIN-93G as control (C) [35] and treatment groups with C+
Synergy1 (5%, 10%), C+ SM (5%, 10%), C+ Synergy1 +
SM (5% + 5%), (10% + 10%), (5% + 10%), and (10% +
5%). Dietary modiﬁcations were made to ﬁber, casein, and
cornstarch (Table 1). All rats were housed and maintained
according to standard protocols. Biweekly body weights and
daily feed intakes were recorded. The diets were prepared
fresh and stored at 4◦C. Dietary ingredients were obtained
from MP Biomedicals, Costa Mesa, CA. Synergy1 (Beneo)
was obtained from Orafti (Teinen, Belgium) and SM was
obtained from the local market (Garden Cove, Huntsville,
AL). The Institutional Animal Care and Use Committee of
Alabama A&M University approved all protocols involving
the experiment.
2.2. Carcinogen Injection. All rats except saline controls
received two subcutaneous injections of AOM in saline
(National Chemical Repository, Kansas City, MO) for ACF
induction at 16mg/kg body at 7 and 8 weeks of age. At
17 weeks of age, rats were killed using CO2 asphyxiation
following an overnight fast.
2.3.SampleCollection. Thececumfromeachratwasexcised,
weighed and split open, and the pH of the cecal content was
measured. Livers of rats were excised and stored at −80◦C
until analysis.
2.4. Enumeration of Aberrant Crypt Foci (ACF). Aberrant
crypt foci scoring (ACF) was done as described by Bird [36].
Brieﬂy, excised colons were ﬂushed with phosphate buﬀer
solution (0.1M, pH 7.2) (Fisher Scientiﬁc, Suwannee, GA)
ﬁxed on ﬁlter paper with 10% buﬀered formalin (Fisher
Scientiﬁc, Suwannee, GA). Fixed colons were sectioned into
proximal (closer to the cecum) and distal portions (closer
to the rectal end) of equal length. The colon segments were
stained with a 0.2% methylene blue solution (Sigma chemi-
cals, St. Louis, MO), and ACF were scored microscopically.
2.5. Preparation of Liver Samples for Measuring Hepatic
EnzymeActivity. Onegramofliversamplewashomogenized
in 10mL of potassium phosphate buﬀer (pH 7.2, 0.1M)
using a Potter-Elvehjem homogenizer (Model 985370-
395, Fisher Scientiﬁc, Suwannee, GA). The homogenate
was centrifuged (Eppendorf AG-5418, Fisher Scientiﬁc,
Suwannee, GA) at 10,000×g for 30min and the supernatant
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Table 2: Feed intake, weight gain, cecal weight, and cecal pH in rats fed Synergy1 and Soybean meal.
Groups Feed intake g/day/rat Weight gain (g) Cecal weight (g) Cecal wall (g) Cecal pH
Control 17.53 ±0.19a 275.67 ±9.60a 2.58 ±0.18c 1.02 ±0.10c 7.40 ±0.04a
Syn1 5% 16.77 ±0.19a 278.33 ±6.64a 3.04 ±0.55bc 2.0 ±0.30b 6.79 ±0.90b
Syn1 10% 16.15 ±0.47a 253.33 ±10.90a 5.89 ±0.13a 3.02 ±0.06a 6.26 ±1.00bc
SM 5% 16.59 ±0.22a 254.00 ±12.22a 2.91 ±0.60c 1.51 ±0.49c 7.00 ±1.22a
SM 10% 17.29 ±0.59a 257.33 ±13.73a 2.91 ±0.08c 1.32 ±0.07c 7.06 ±0.82a
S y n 15 %+S M5 % 1 6 .91 ±0.11a 266.00 ±10.69a 3.70 ±0.14b 2.06 ±0.04b 6.22 ±0.74bc
Syn1 10% + SM 10% 16.73 ±0.16a 257.00 ±9.07a 5.16 ±0.78a 3.87 ±0.19a 5.99 ±0.20c
Syn1 5% + SM 10% 17.65 ±0.07a 250.67 ±2.02a 2.75 ±0.21c 2.33 ±0.19b 6.62 ±1.11b
S y n 11 0 %+S M5 % 1 6 .72 ±0.81a 256.33 ±15.37a 5.12 ± 0.71ab 3.76 ±0.11a 6.10 ±0.59c
Values are expressed as means ± SEM, n = 3.
abcMeans in the same column with the same letter are not signiﬁcantly diﬀerent by Tukey’s studentized range test (P ≤ .05).
Abbreviations used: Syn1: Synergy1 and SM: Soybean meal.
Table 3: Eﬀect of Synergy1 and Soybean meal on incidence of aberrant crypt foci (ACF) in colon of Fisher 344 male rats.
Groups Proximal Colon Distal Colon Total Colon
Control (AIN-93G) 49 ±9.21a 101 ±11.6a 150a
Syn1 5% 23 ±1.5b 38 ±4.1b 61b
Syn1 10% 17 ±4.9bc 37 ±12.4b 54b
SM 5% 24 ±3.0b 48 ±4.0b 72b
SM 10% 19 ±2.8bc 44.5 ±6.8b 63.5b
S y n 15 %+S M5 % 1 2±5.5bc 32 ±8.4bc 42c
Syn1 10% + SM 10% 9 ±2.5c 32 ±4.4bc 41c
Syn1 5% + SM 10% 4 ±1.7c 51 ±5.2b 49bc
S y n 11 0 %+S M5 % 7±2.4c 27 ±5.2c 34c
Values are expressed as means ± SEM; n = 3.
abcMeans in the same column with the same letter are not signiﬁcantly diﬀerent by Tukey’s studentized range test (P<. 05).
Abbreviations used: Syn1: Synergy1 and SM: Soybean meal.
2.6. Glutathione-S-Transferase (GST) Activity. The super-
natant from liver samples was mixed with 1, chloro
2, 4-dinitrobenzene (1mM), potassium phosphate buﬀer
(0.1M), and glutathione (1mM). Sample (50–100μL) was
analyzed using a Cary1/3 UV/VIS dual beam spectropho-
tometer (Varian, Palo Alto, CA) at 340nm. The total enzyme
a c t i v i t yw a sm e a s u r e da tt h ee n do f5m i no fr e a c t i o n .
2.7. Reduced Glutathione (GSH) Assay. Hepatic GSH was
estimated using Ellman’s reagent [37]. An aliquot of the
homogenate was deproteinized by the addition of an
equal volume of 4% sulfosalicylic acid and centrifuged at
17,000×gf o r1 5 m i na t2 ◦C. To the diluted supernatant
(0.5mL), 4.5mL of Ellman’s reagent was added. Absorbance
was read at 412nm.
2.8. Catalase (CAT) Assay. Hepatic catalase activity was
estimated at 240nm by monitoring the decomposition of
H2O2 [38]. The reaction mixture (1mL) contained 0.02mL
ofliverhomogenateinphosphatebuﬀer(50mM,pH7.0)and
0.1mLof30mMH 2O2 in phosphate buﬀer.
2.9. Superoxide-Dismutase (SOD) Assay. Hepatic superox-
ide-dismutase was assayed as described by Fridovich [39].
To the supernatant (2.0mL), 2.5mL of 0.05M carbonate
buﬀer and 0.3mM adrenaline were added and absorbance
was measured at 480nm.
2.10. Bone Mineralization. Speciﬁc minerals (Calcium (Ca),
Phosphorus (P), Magnesium (Mg), Iron (Fe) and Zinc (Zn))
in femur bone samples were quantiﬁed using inductively
coupled plasma spectroscopy (ICP) following standard pro-
tocol AACC Method [40].
2.11. Statistical Analysis. Data were analyzed (n: tripli-
cates) using SAS 9.1 statistical program (SAS, Cary, NC).
Results were analyzed by analysis of variance (ANOVA) and
expressed as means ± SEM. Means were separated using
Tukey’s studentized range test. Signiﬁcant diﬀerences (P<
.05) were determined using one-way ANOVA.
3. Results and Discussion
3.1. Feed Intake, Weight Gain, Cecal Weight, and Cecal
pH. There were no signiﬁcant diﬀerences in feed intake
(g) and weight gain (g) among groups (Table 2). Weight
gain (278.3g) was the highest in rats fed SM (5%). Cecal
weight was signiﬁcantly (P<. 05) higher in treatment4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 4: Eﬀect of Synergy1 and Soybean meal on total number of AOM-induced Crypts in Fisher 344 male Rats.
Groups Proximal colon Distal colon Total colon
Control 141 ±24.89a 310 ±40.53a 444a
Syn1 5% 53 ±5.1bc 136 ±10.8b 189bc
Syn1 10% 46 ±10.6bc 128 ±28.3b 174c
SM 5% 72 ±6.1b 152 ±12.9b 224b
SM 10% 62 ±8.8b 140 ±26.2b 202b
S y n 15 %+S M5 % 3 1 .5 ±17.1d 106 ±30.2c 137.5d
Syn1 10% + SM 10% 28 ±7.5d 91 ±10.3c 116e
Syn1 5% + SM 10% 22 ±10.4d 121 ±19.0b 144d
S y n 11 0 % +S M5 % 2 7±7.1d 72 ±15.0d 99e
Values are expressed as means ± SEM; n = 3.
abcdeMeans in the same column with the same letter are not signiﬁcantly diﬀerent by Tukey’s studentized range test (P<. 05).
Abbreviations used: Syn1: Synergy1, SM: Soybean meal.
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Figure 1: Reductions in azoxymethane-induced aberrant crypt foci
compared to the control. Abbreviations used: Syn1: Synergy1 and
SM: Soybean meal.
groups compared to rats fed the control diet. Rats fed Syn1
(10%) singly and Syn1 + SM (10%) in combination had
signiﬁcantly (P<. 05) higher cecal weight compared to the
other treatment groups (Table 2). Cecal pH ranged from a
high of 7.40 in rats fed the control diet to a low of 5.99 in the
rats fed Syn1 + SM (10%). Rats fed treatment diets excluding
SM (5%) and SM (10%) had signiﬁcantly (P<. 05) lower
cecal pH compared to the rats fed the control diet (Table 2).
The groups fed Syn1 + SM (5 + 5%) and Syn1 + SM (10 +
5%) had the lowest cecal pH among groups fed combination
diets.
3.2. Incidence of Aberrant Crypt Foci. Incidence of ACF in
the distal colon was signiﬁcantly (P<. 05) higher compared
to the proximal colon. These results are consistent with
previous reported studies [41, 42]. Rats fed treatment diets
had signiﬁcantly (P<. 05) lower number of ACF in the distal
and proximal colon compared to the rats fed the control
diet (Table 3). The rats fed the control diet had the highest
number of ACF while the group fed Syn1 (10%) + SM (5%)
had the lowest number of ACF with a 77.3% reduction,
compared to the control. Total ACF (Table 3)r a n g e df r o m
a high of 150 in the control rats to a low of 34 in the rats fed
Syn1 (10) + SM (5%). Reductions in total ACF compared
to the control in rats fed the treatment diets ranged from a
high of 77.3% in the group fed Syn1 (10) + SM (5%) to a
low of 52% in the group fed SM (5%) (Figure 1). The groups
fed the combination diet with higher concentrations of Syn1
(10%) + SM (10%) had the greatest reductions in ACF.
Feeding Syn1 and SM alone at 5% and 10% resulted in lower
reductions of 59, 64, 52 and 57.6%, respectively, compared
to the control. However, when Syn1 was fed in combination
with SM at both 5% and 10% levels, the reductions were
greatly enhanced (75–91% in the proximal and 49–73% in
the distal colon compared to the control fed group).
3.3. Total Crypts. Total colonic crypts are precise indicators
of the chemopreventive eﬀect of a nutrient or food since it
takes into account both the ACF as well as crypts per focus.
Total crypts were signiﬁcantly (P<. 05) higher in the rats fed
the control compared to those fed treatment diets. Rats fed
Syn1 + SM (5%) and Syn1 + SM (10%), Syn1 (10%) + SM
(5%) and Syn1 (5%) + SM (10%) had signiﬁcantly (P<. 05)
lower number of total crypts compared to the other groups
fed treatment diets. Total crypts ranged from a high of 440
in the control rats to a low of 99 in the rats fed Syn1 (10%)
+ SM (5%). The reduction in total crypts was enhanced with
the addition of SM to Syn1 (Table 4). The reductions in total
crypts compared to the control ranged from a low of 49.54%
in the group fed SM (5%) to a high of 77.70% in the rats fed
Syn1 (10%) + SM (5%).
3.4. Hepatic GST, GSH, CAT, and SOD. GST activity
(μmol/mg) in the treatment groups was signiﬁcantly (P<
.05) higher (21.68 to 26.77μmol/mg) compared to the
control group (10.58μmol/mg) (Table 5). GST activity in
the treatment groups was 51 to 60% higher compared to
the control. A similar trend was observed with GSH levels;
however GSH levels (mM) were over 90% higher in the
treatmentgroupscomparedtothecontrol(Table 5).Catalase
(CAT) activity (μmol/mL) in the liver of rats fed the control
diet (0.055) (Table 5) was signiﬁcantly (P<. 05) lower
compared to the treatment groups. Rats fed treatment dietsJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
Table 5: Eﬀect of Synergy1 and Soybean meal on glutathione S-transferase, catalase, and superoxide-dismutase activities and reduced
glutathione level in Fisher 344 male rats.
Groups GST (μmol/mg) GSH (mM) CAT (μmol/mL) SOD (μmol/mL)
Control (AIN-93G) 10.58 ±0.32b 0.17 ±0.13b 0.055 ±1.50b 0.107 ±0.008b
Syn1 5% 25.03 ±0.81a 2.15 ±0.12a 0.184 ±0.02a 0.176 ±0.013a
Syn1 10% 21.68 ±1.85a 2.48 ±0.13a 0.170 ±0.01a 0.185 ±0.001a
SM 5% 26.77 ±2.56a 2.18 ±0.28a 0.133 ±0.23a 0.184 ±0.008a
SM 10% 24.31 ±0.38a 2.37 ±0.78a 0.112 ±0.01a 0.190 ±0.009a
Syn1 5% +SM 5% 25.11 ±2.28a 2.53 ±0.27a 0.149 ±0.04a 0.187 ±0.007a
Syn1 10%+SM 10% 26.01 ±4.04a 2.98 ±0.16a 0.330 ±0.19a 0.186 ±0.005a
Syn1 5% +SM 10% 21.81 ±0.71a 2.10 ±0.19a 0.145 ±0.02a 0.190 ±0.006a
S y n 11 0 % +S M5 % 2 5 .28 ±1.56a 2.13 ±0.09a 0.127 ±0.03a 0.186 ±0.003a
Values are expressed as means ± SEM; n = 3.
abcMeans in the same column with the same letter are not signiﬁcantly diﬀerent by Tukey’s studentized range test (P<. 05).
Abbreviations used: Syn1: Synergy1, SM: Soybean meal, GST: Glutathione S-transferase, GSH: reduced glutathione, CAT: catalase, and SOD: superoxide
dismutase.
Table 6: Eﬀect of control and treatment diets on Bone mineralization.
Groups Ca (mg/g) P (mg/g) Mg (mg/g) Fe (μg/g) Zn (μg/g)
Control 268.5 ±11.2b 122.4 ± 1.2d 2.2 ±0.1c 53.1 ±0.8b 163.9 ±24.8b
Syn1 5% 373.1 ±2.7a 145.7 ±1.3bc 3.1 ±0.05ab 63.0 ±3.3ab 218.6 ± 3.6ab
Syn1 10% 374.6 ±5.7a 147.3 ±2.6bc 3.1 ±0.06ab 65.6 ±0.5ab 231.4 ± 6.0a
SM 5% 393.2 ±18.9a 147.4 ±3.0bc 3.1 ±0.03ab 63.9 ±2.5ab 227.4 ±19.3a
SM 10% 353.3 ±12.8a 142.6 ±1.5c 2.8 ±0.08b 58.4 ±4.0ab 214.0 ±11.9ab
S y n1+S M5 % 4 1 6 .3 ±6.8a 152.4 ±1.2b 3.3 ±0.1a 67.4 ±4.6a 249.6 ± 5.3a
S y n1+S M1 0 % 417.6 ±32.4a 166.2 ±1.3a 3.4 ±0.1a 70.7 ±2.9a 250.3 ±5.0a
Syn1 5% + SM 10% 394.8 ±2.8a 153.9 ±1.1b 3.3 ±0.09a 66.1 ±2.4ab 246.2 ± 6.6a
Syn1 10% + SM 5% 396.3 ±6.5a 152.1 ±2.2b 3.2 ±0.07ab 66.6 ±1.5ab 236.2 ± 1.7a
Values are means ± SEM; n = 3.
abcdMeans in a column with same superscripts do not signiﬁcantly diﬀer (P<. 05).
Abbreviations: Syn1: Synergy1; SM: Soybean meal; Ca: calcium; P: phosphorous, Mg: magnesium; Fe: iron; Zn: zinc.
had 51 to 80% higher CAT activity (μmol/mL) compared to
those fed the control diet. Among the rats fed treatments
diets, CAT activity was the highest in the rats fed Syn1
+ SM (10%) (0.330) which accounted for an increase of
83% compared to the control, and the lowest activity was
seen in the rats fed SM (10%) (0.112) accounting for an
i n c r e a s eo f5 1 %c o m p a r e dt ot h ec o n t r o l .T h e r ew e r en o
diﬀerences in CAT activity among treatment groups. SOD
activity (μmol/mL) did not diﬀer among rats fed control
and treatment diets. However, rats fed the control diet had
a lower (0.107) SOD activity (μmol/mL) compared to those
fed treatment diets (0.176 to 0.190).
3.5. Bone Mineralization. Speciﬁc minerals in bone femurs
(Ca, P, Mg, Fe, and Zn) were signiﬁcantly (P<. 05)
higher in treatment groups compared to control (Table 6).
Among treatment groups, rats fed Syn1 + SM (10% + 10%)
showed the highest retention of these minerals. Calcium
(mg/g) retention in rats fed treatment diets in combinations
was over twice compared to the control. Calcium and
phosphorus form major composition of bone and involved
in its remodeling process.
4. Discussion
The ACF model has been used [43–46] to study dietary
modulation of colon carcinogenesis. Weight gain and feed
intakes among control and treatment groups were similar.
Average feed intake ranged from ≈16 to 18g/day. Feeding
functional foods or dietary ingredients has been reported to
aﬀect weight gain in some published studies [47]. However,
other researchers [48] did not observe any diﬀerences in
weight gain or feed intake. Rats fed diets containing Syn1
(10%) singly and in combination with Soybean meal had
signiﬁcantly (P<. 05) lower cecal pH and higher cecal
weightwhichisconsistentwithpreviousstudies[49,50].The
fermentation of soluble ﬁber by colonic microﬂora results
in the production of SCFA which leads to an increase in
cecal weight and decrease in cecal pH. Feeding rats with
diets containing 0.3% grapefruit ﬂavonoid extract, 5% or
10% Inulin, andacombination ofboth supplementsresulted6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
in a signiﬁcant enlargement of the cecum compared to rats
fed the control diet. Presence of dietary Inulin resulted in a
larger cecal mass, over 4-fold higher than the control [51].
Inulin and soybean meal are both signiﬁcant sources of ﬁber.
Fermentation of ﬁber leads to the production of short-chain
fatty acids such as butyric, propionic, acetic acid, and some
gases. Butyrate is the preferred fuel for colonic mucosal cells
[52]. Fiber can also increase fecal weight and speed intestinal
transit.
Synergy1 singly and in combination with probiotics
exhibited antitumorigenic activity against AOM-induced
colon carcinogenesis which was explained by an increased
production of cecal short-chain fatty acids (SCFAs) [53].
Prebiotics may modify the activity of beneﬁcial intestinal
microﬂora as a result of the lower cecal pH resulting in
increased solubility of minerals such as calcium in acidic
environment that may aid in bone and colonic health as well
as increased isoﬂavone bioavailability [54].
Nutrients play a signiﬁcant role in induction or inhibi-
tionofenzymeactivitiessuchasPhase1andPhase2enzymes
that oﬀer protection against xenobiotics by their detoxifying
activity [55, 56]. Glutathione S-transferase (GST) is a phase
2 enzyme involved in conjugation and detoxiﬁcation of
potentialcarcinogensanditsactivityisenhancedbyproducts
of gut fermentation, such as SCFA [57–59]. Results from our
study showed a signiﬁcantly (P<. 05) higher GST activity
among treatment groups compared to the control.
A similar study conducted using dietary fructo-oligosac-
charides and isoﬂavone conjugates in ovariectomized mice
showed increased β-glucosidase activity, equol production,
and femoral bone mineral density representing contribution
of FOS in increasing bioavailability of isoﬂavones [60].
Defatted Soybean meal ﬂour and whole Soybean meal, good
sourcesofisoﬂavonesreducedtheearlystagesofcoloncancer
[61].
Results indicate that feeding Synergy1 in combination
with Soybean meal had protective eﬀects in reducing AOM-
induced aberrant crypt foci in Fisher 344 male rats. One
of the mechanisms that may explain the chemopreventive
potential of Syn1 is the modulation of beneﬁcial gut
microﬂora (equol producing) by fermentation in the distal
colon aﬀecting soybean metabolism. Feeding Synergy1 and
Soybean meal singly and in combination also enhanced the
activity of antioxidative and detoxiﬁcation enzymes which
may have played a signiﬁcant role in reducing AOM-induced
ACF.
5. Conclusions
Feeding Synergy1 and Soybean in combination showed their
potential health beneﬁts in prevention of aberrant crypt foci
in F344 male rats. However, ACF studies in rodents may be
limited to evaluate the eﬀects of functional foods over longer
duration as advancement in cancer pathology is complex
whereACFvaluetopredicttumoroutcomemaydecline[62].
Studies evaluating the combinational eﬀects of Synergy1
and Soybean on end point tumor biomarkers, colon cancer
speciﬁcgenes,andsignalingpathwaysmayprovideaninsight
on their synergism contributing to colon cancer prevention.
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